NEUROPSIQUIATRÍA DE LA ENCEFALITIS POR ANTICUERPOS CONTRA EL RECEPTOR NMDA

Autores/as

Palabras clave:

síntomas neuropsiquiátricos, encefalitis autoinmune NMDAr, presentación clínica

Resumen

La encefalitis por anticuerpos contra el receptor anti-N-metil-D-aspartato (NMDA) es una entidad clínica potencialmente letal perteneciente al grupo de las encefalitis mediadas por anticuerpos contra proteínas sinápticas. En esta se demuestran anticuerpos IgG contra el receptor de NMDA (NMDAr), asociados a la presencia de síntomas psiquiátricos y neurológicos que se desarrollan por estadios en el curso de la enfermedad. El predominio de síntomas neuropsiquiátricos en las etapas tempranas provoca que un elevado porcentaje de pacientes busquen evaluación psiquiátrica como un primer contacto con el sistema de salud. Por esta razón, es vital que los médicos reconozcan esta entidad como un diagnóstico diferencial importante en la práctica clínica, puesto que, a pesar de la gravedad de esta condición, más del 75% de los pacientes logran una recuperación sustancial con un tratamiento adecuado y oportuno. Presentamos una revisión de la literatura sobre esta enfermedad con especial énfasis en los aspectos neuropsiquiátricos.

Citas

Zhang L, Wu M-Q, Hao Z-L, Chiang SMV, et al. Clinical characteristics, treatments, and outcomes of patients with anti- N -methyl- d -aspartate receptor encephalitis: A systematic review of reported cases. Epilepsy Behav. 2017;68:57-65.

Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63-74.

Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404.

Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-8.

Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-65.

Maneta E, Garcia G. Psychiatric Manifestations of Anti-NMDA Receptor Encephalitis: Neurobiological Underpinnings and Differential Diagnostic Implications. Psychosomatics. 2014;55(1):37-44.

Dalmau J, Graus F. Antibody-Mediated Encephalitis. Ropper AH, editor. N Engl J Med. 2018;378(9):840-51.

Vitaliani R, Mason W, Ances B, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005;58(4):594-604.

Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25-36.

Eker A, Saka E, Dalmau J, et al. Testicular teratoma and anti-N-methyl-D-aspartate receptor-associated encephalitis. J Neurol Neurosurg Psychiatry. 2008;79(9):1082-3.

Guasp M, Dalmau J. Encefalitis por anticuerpos contra el receptor de NMDA. Med Clínic. 2018;151(2):71-79.

Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10(12):835-44.

Gable MS, Sheriff H, Dalmau J, et al. The Frequency of Autoimmune N-Methyl-D-Aspartate Receptor Encephalitis Surpasses That of Individual Viral Etiologies in Young Individuals Enrolled in the California Encephalitis Project. Clin Infect Dis. 2012;54(7):899-904.

Huang Q, Wu Y, Qin R, et al. Clinical characteristics and outcomes between children and adults with anti-N-Methyl-d-Aspartate receptor encephalitis. J Neurol. 2016;263(12):2446-55.

Irani SR, Vincent A. NMDA Receptor Antibody Encephalitis. Curr Neurol Neurosci Rep. 2011;11(3):298-304.

Dalmau J. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: The 2016 Cotzias Lecture. Neurology. 2016;87(23):2471-82.

Bortnick A, Allman D. What Is and What Should Always Have Been: Long-Lived Plasma Cells Induced by T Cell-Independent Antigens. J Immunol. 2013;190(12):5913-8.

Armangue T, Moris G, Cantarín-Extremera V, et al. Autoimmune post–herpes simplex encephalitis of adults and teenagers. Neurology. 2015;10-1212.

Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol. 2001;11(3):327-35.

Corlew R, Brasier DJ, Feldman DE, et al. Presynaptic NMDA Receptors: Newly Appreciated Roles in Cortical Synaptic Function and Plasticity. The Neuroscientist. 2008;14(6):609-25.

Steffens M, Huppertz H-J, Zentner J, et al. Unchanged glutamine synthetase activity and increased NMDA receptor density in epileptic human neocortex: Implications for the pathophysiology of epilepsy. Neurochem Int. 2005;47(6):379-84.

Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999;33(6):523-33.

Huang Q, Xie Y, Hu Z, et al. Anti-N-methyl-D-aspartate receptor encephalitis: A review of pathogenic mechanisms, treatment, prognosis. Brain Res. 2020; 15;1727:146549.

Hirohata S, Tanaka K. Differential expression of antibodies to NMDA receptor in anti-NMDA receptor encephalitis and in neuropsychiatric systemic lupus erythematosus. Lupus Sci Med. 2019; 13;6(1):e000359.

Arinuma Y. Antibodies and the brain: anti-N-methyl-D-aspartate receptor antibody and the clinical effects in patients with systemic lupus erythematosus. Curr Opin Neurol. 2018;1.

Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199-214.

Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophr Res. 2016;176(1):36-40.

Moghaddam B, Javitt D. From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment. Neuropsychopharmacology. 2012;37(1):4-15.

Lynch DR, Rattelle A, Dong YN, et al. Anti-NMDA Receptor Encephalitis: Clinical Features and Basic Mechanisms. Adv Pharmacol. 2018;82:235-260.

Wang R, Lai X, Liu X, et al. Brain magnetic resonance-imaging findings of anti-N-methyl-d-aspartate receptor encephalitis: a cohort follow-up study in Chinese patients. J Neurol. 2018;265(2):362-9.

Catani M, Dell’Acqua F, Thiebaut de Schotten M. A revised limbic system model for memory, emotion and behaviour. Neurosci Biobehav Rev. 2013;37(8):1724-37.

Parenti A, Jardri R, Geoffroy PA. How Anti-NMDAR Encephalitis Sheds Light on the Mechanisms Underlying Catatonia: The Neural Excitatory/Inhibitory Imbalance Model. Psychosomatics. 2016;57(3):336-8.

Finke C, Kopp UA, Pajkert A, et al. Structural Hippocampal Damage Following Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Biol Psychiatry. 2016;79(9):727-34.

Dalmau J, Armangué T, Planagumà J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(11):1045-1057.

Barry H, Hardiman O, Healy DG, et al. Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis. Br J Psychiatry. 2011;199(06):508-9.

Chapman MR, Vause HE. Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment. Am J Psychiatry. 2011;168(3):245-51.

Schieveld JNM, Strik JJMH, van Kraaij S, et al. Psychiatric manifestations and psychopharmacology of autoimmune encephalitis: A multidisciplinary approach. Handb Clin Neurol. 2019;165:285-307.

Gibson LL, Pollak TA, Blackman G, et al. The Psychiatric Phenotype of Anti-NMDA Receptor Encephalitis. J Neuropsychiatry Clin Neurosci. 2019; 31(1):70-79.

Liu C, Zhu J, Zheng X-Y, et al. Anti-N-Methyl-D-aspartate Receptor Encephalitis: A Severe, Potentially Reversible Autoimmune Encephalitis. Mediators Inflamm. 2017;2017:1-14.

Barry H, Byrne S, Barrett E, et al. Anti- N -methyl-d-aspartate receptor encephalitis: review of clinical presentation, diagnosis and treatment. BJPsych Bull. 2015;39(1):19-23.

Maat P, de Graaff E, van Beveren NM, et al. Psychiatric phenomena as initial manifestation of encephalitis by anti‐NMDAR antibodies. Acta Neuropsychiatr. 2013;1-9.

Warren N, Siskind D, O’Gorman C. Refining the psychiatric syndrome of anti- N -methyl- D -aspartate receptor encephalitis. Acta Psychiatr Scand. 2018;138(5):401-8.

Foley SR, Kelly BD, Clarke M, et al. Incidence and clinical correlates of aggression and violence at presentation in patients with first episode psychosis. Schizophr Res. 2005;72(2-3):161-8.

Compton MT, Fantes F, Wan CR, et al. Abnormal movements in first-episode, nonaffective psychosis: Dyskinesias, stereotypies, and catatonic-like signs. Psychiatry Res. 2015;226(1):192-7.

Waters F, Collerton D, ffytche DH, et al. Visual Hallucinations in the Psychosis Spectrum and Comparative Information From Neurodegenerative Disorders and Eye Disease. Schizophr Bull. 2014;40(Suppl_4):S233-45.

Espinola-Nadurille M, Bustamante-Gomez P, Ramirez-Bermudez J, Bayliss L, Rivas-Alonso V, Flores-Rivera J. Frequency of neuropsychiatric disturbances in anti-NMDA receptor encephalitis. Acta Psychiatr Scand. 2018;138(5):483-5.

Fink M, Taylor MA. The Catatonia Syndrome: Forgotten but Not Gone. Arch Gen Psychiatry. 2009;66(11):1173.

Kayser MS, Titulaer MJ, Gresa-Arribas N, et al. Frequency and Characteristics of Isolated Psychiatric Episodes in Anti– N -Methyl- D -Aspartate Receptor Encephalitis. JAMA Neurol. 2013;70(9):1133.

Kataoka H, Takatani T. Psychiatric Symptoms and Electroencephalograms in Anti-NMDAR Encephalitis. Neuropsychiatry. 2018; 8(1):38–41

Reid DK, Clardy SL. Anti-NMDA-receptor encephalitis: unusual presentation of an uncommon condition. J Neurol Neurosurg Psychiatry. 2013;84(1):69-70.

Liu X, Yan B, Wang R, et al. Seizure outcomes in patients with anti-NMDAR encephalitis: A follow-up study. Epilepsia. 2017;58(12):2104-11.

Viaccoz A, Desestret V, Ducray F, et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology. 2014;82(7):556-63.

Kleinig TJ, Thompson PD, Matar W, et al. The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord. 2008;23(9):1256-61.

Muñoz-Lopetegi A, Graus F, Dalmau J, et al. Sleep disorders in autoimmune encephalitis. Lancet Neurol. 2020;19(12):1010-1022.

Schmitt SE, Pargeon K, Frechette ES, et al. Extreme delta brush: A unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012;79(11):1094-100.

Freund B, Ritzl EK. A review of EEG in anti-NMDA receptor encephalitis. J Neuroimmunol. 2019 Jul 15;332:64-68.

Yu Y, Wu Y, Cao X, et al. The Clinical Features and Prognosis of Anti-NMDAR Encephalitis Depends on Blood Brain Barrier Integrity. Mult Scler Relat Disord. 2021;47:102604.

Espinola-Nadurille M, Bautista-Gomez P, Flores J, et al. Non-inflammatory cerebrospinal fluid delays the diagnosis and start of immunotherapy in anti-NMDAR encephalitis. Arq Neuropsiquiatr. 2018;76(1):2-5.

Probasco JC, Solnes L, Nalluri A, et al. Decreased occipital lobe metabolism by FDG-PET/CT: An anti–NMDA receptor encephalitis biomarker. Neurol - Neuroimmunol Neuroinflammation. 2018;5(1):e413.

Lennox BR, Coles AJ, Vincent A. Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br J Psychiatry. 2012;200(02):92-4.

Steiner J, Walter M, Glanz W, et al. Increased Prevalence of Diverse N -Methyl-D-Aspartate Glutamate Receptor Antibodies in Patients with an Initial Diagnosis of Schizophrenia: Specific Relevance of IgG NR1a Antibodies for Distinction From N -Methyl-D-Aspartate Glutamate Receptor Encephalitis. JAMA Psychiatry. 2013;70(3):271.

Restrepo Martínez M, Paola Bautista G, Espínola-Nadurille M, Bayliss L. Banderas rojas para sospechar encefalitis anti-NMDAr en un primer episodio psicótico: reporte de dos casos. Rev Colomb Psiquiatr.2017

González-Valcárcel J, Rosenfeld MR, Dalmau J. Differential Diagnosis of Encephalitis due to Anti-NMDA Receptor Antibodies. Neurol Engl Ed. 2010;25(7):409-13.

Zhang Y, Liu G, Jiang M, et al. Efficacy of Therapeutic Plasma Exchange in Patients with Severe Refractory Anti-NMDA Receptor Encephalitis. Neurotherapeutics. 2019;16(3):828-837.

Kuppuswamy PS, Takala CR, Sola CL. Management of psychiatric symptoms in anti-NMDAR encephalitis: a case series, literature review and future directions. Gen Hosp Psychiatry. 2014;36(4):388-91.

S. Kayser M, Dalmau J. Anti-NMDA Receptor Encephalitis in Psychiatry. Curr Psychiatry Rev. 2011;7(3):189-93.

Lejuste F, Thomas L, Picard G, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol - Neuroimmunol Neuroinflammation. 2016;3(5):e280.

Fink M. Rediscovering catatonia: the biography of a treatable syndrome. Acta Psychiatr Scand. 2013;127:1-47.

Warren N, Grote V, O'Gorman C, et al. Electroconvulsive therapy for anti-N-methyl-d-aspartate (NMDA) receptor encephalitis: A systematic review of cases. Brain Stimul. 2019;12(2):329-334.

Santoro JD, Filippakis A, Chitnis T. Ketamine use in refractory status epilepticus associated with anti-NMDA receptor antibody encephalitis. Epilepsy Behav Rep. 2019; 23;12:100326.

Xu X, Lu Q, Huang Y, et al. Anti-NMDAR encephalitis: A single-center, longitudinal study in China. Neurol Neuroimmunol Neuroinflamm. 2019; 16;7(1):e633.

Finke C, Kopp UA, Prüss H, et al. Cognitive deficits following anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry. 2012;83(2):195-8.

McKeon GL, Robinson GA, Ryan AE, et al. Cognitive outcomes following anti-N-methyl-D-aspartate receptor encephalitis: A systematic review. J Clin Exp Neuropsychol. 2018;40(3):234-52.

Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014;13(2):167-77.

Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-8.

Wang K, Chen Z, Wu D, et al. Early second-line therapy is associated with improved episodic memory in anti-NMDA receptor encephalitis. Ann Clin Transl Neurol. 2019;6(7):1202-1213.

Publicado

2021-10-13

Número

Sección

Artículos de revisión